A multi-omics study of lyophilized fecal microbiota transplantation and bacteria-free sterile fecal filtrate in recurrent ...

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

For adults with laboratory-confirmed Clostridioides difficile infection (CDI) at high risk for recurrence, high-dose VE303, a defined bacterial consortium of eight strains of commensal Clostridia, ...

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments. According to some data, ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

In a recent review published in BMC Infectious Diseases, researchers reviewed existing data on Clostridioides difficile infections (CDI) among United States residents. CDIs have caused considerable ...

This article first appeared on ContagionLive.com. With newer modalities and therapies for Clostridioides difficile infections (CDI) coming online, there is a need for more studies and an understanding ...

VIENNA, May 5, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an ...